I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
To judge the first 100 days of a new administration is, as many pundits have pointed out, an odd vestige of history, more convenient than significant. Which is why we’ll start... Read more »
[Corrected 4/25/17, 12:30 p.m. See below.] About 7,000 liver transplants occur in the U.S. each year. A condition that few people can pronounce, and no one has a treatment... Read more »
After three years of planning, a long-range health study from the biotech group at the former Google has begun.
Verily, the life sciences arm of Google’s parent company Alphabet, is funding... Read more »
In the nation’s capital, healthcare and life sciences were on center stage. Or stages, actually. On Capitol Hill, FDA commissioner nominee Scott Gottlieb, the drug industry’s favorite pick, told senators his... Read more »
The American Association for Cancer Research held its annual meeting this week in Washington, DC, a convenient venue for former Vice President Joe Biden to deliver a broadside against the Trump... Read more »
In what passes for a short hearing these days in Washington, DC, the Trump White House’s pick to run the Food and Drug Administration, Scott Gottlieb, spent less than three hours... Read more »
For the more severe cases of eczema—inflamed skin that can range from annoying dry patches to painful swelling, oozing, and cracking—there’s a new injectable medicine on the market that will cost... Read more »
It’s been more than a year since an infamous party with hired models in cocktail dresses captured the biotech community’s attention at the 2016 J.P. Morgan conference.
There has been plenty... Read more »
If it wasn’t clear that the Trump administration disdained most types of scientific inquiry and practice, the White House’s proposed budget drove the point home. The top-line figures: a nearly 20... Read more »
One of the companies trying to revive the once-failed notion of xenotransplantation—transplanting animal organs or tissues into humans—has raised a significant round of cash.
The $38 million Series A round announced... Read more »
After years of investing Bill Gates’s money and giving him scientific advice, two of the software billionaire’s associates have launched their own $200 million healthcare fund. Some of biotech’s highest-profile bets... Read more »
It’s a struggle that comic-book fans know well. Ordinary people, bestowed with super powers from a spider bite or gamma rays, struggle to harness their own abilities.
T cells, key soldiers... Read more »
In an address to Congress this week, President Donald Trump outlined many of his near-term goals, including an overhaul of the Affordable Care Act, also known as Obamacare, even as public... Read more »
Kite Pharma released more data this morning that it hopes will lead this year to the first commercial approval of a cutting-edge cancer treatment known as CAR-T therapy.
The Santa Monica,... Read more »
The U.S. Patent and Trademark Office has made a decision in the patent fight over ownership of the landmark CRISPR-Cas9 gene editing technology. The ruling is in favor of the Broad... Read more »
Another Alzheimer’s drug has failed a major test. Merck (NYSE: MRK) reported late Tuesday that its pill verubecestat was not helping people with significant Alzheimer’s symptoms. The drug maker announced that... Read more »
The biotech community pushed back against President Donald Trump’s order to block travelers and refugees this week, and not much later, a federal court did, too. Patient advocates have scored big... Read more »
In the biomedical world, perhaps the biggest question looming over President Donald Trump’s upcoming pick for Food and Drug Administration commissioner is how drastically that person will help roll back FDA... Read more »
© 2007-2017, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.